sarilumab是美國(guó)食品藥品管理局（FDA）在2017年2月批準(zhǔn)的首個(gè)直接靶向IL-6受體復(fù)合α亞基（IL-6Rα）的全人源單克隆IgG抗體，該藥在2016年已在歐盟上市。sarilumab可與IL-6Rα以高親和力結(jié)合，抑制IL-6/IL-6Rα復(fù)合物的形成，進(jìn)而中斷細(xì)胞因子介導(dǎo)的炎癥信號(hào)級(jí)聯(lián)，用于治療對(duì)其他類風(fēng)濕藥無效的成人中度至重度活動(dòng)性類風(fēng)濕關(guān)節(jié)炎，其治療結(jié)果安全有效，并且無嚴(yán)重不良事件報(bào)道。概述sarilumab的藥理作用、臨床研究、不良反應(yīng)等研究進(jìn)展。

Sarilumab is the first full-human monoclonal IgG antibodies that directly target Il-6 receptors combined with IL-6Rα subunit approved by the Food and Drug Administration (FDA) in February 2017, it has appeared on the market in European Union. Sarilumab binds to IL-6Rα receptor with extremely high affinity and inhibits the formation of IL-6/IL-6Rα complex, and thus interrupts the inflammatory signaling cascade mediated by cytokines. Sarilumab can be used to treat adults with moderately to severely active rheumatoid arthritis (RA) that is ineffective for other rheumatoid drugs. The therapeutic outcome is safe and effective, and no serious adverse events were reported. This review summarizes the research progress on the pharmacodynamic properties, the clinical trials, and adverse events of sarilumab so as to provide an alternative therapeutic option for RA patients.